BioMed X launches groundbreaking AI-driven diabetes research in Barbados

With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease

Syngene locks in Bristol Myers Squibb alliance through 2035

The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle

Mahajan Imaging & Labs launches AI-driven blood test to detect Alzheimer’s early

Over 8.8?million Indians aged 60 and above currently live with dementia,

Lantern Pharma launches AI Center of Excellence in Bengaluru to scale precision drug discovery globally

4Moving Biotech bags FDA nod to launch US trial of groundbreaking osteoarthritis therapy

Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function

Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis

The FDA designation follows visual-function results from the Phase 2 ACUITY trial

Alzheimer’s could soon be detected with a simple finger-prick

Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives

MetaVia’s DA-1726 shows breakthrough weight loss in Phase 1 trial

Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit

Edgewise Therapeutics reports positive updates from HCM drug EDG-7500

CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM

AB Science secures US patent for Masitinib in sickle cell disease till 2040

Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain